March 03, 2021 A busy year ahead for Parkinson’s disease As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
December 17, 2020 Novo takes the plunge in Alzheimer’s Novo Nordisk is pushing Rybelsus into a pivotal Alzheimer’s trial despite the failure of the Elad study.
November 03, 2020 AASLD 2020 – Nash updates from Novo and Inventiva in focus At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.